About Anacor Pharmaceuticals
Anacor was a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered and is developing five clinical compounds, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK '052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis.
|
|
|
11-50 employees
View all Anacor Pharmaceuticals employees
|
|
Pharmaceuticals
|
|
1020 East Meadow Circle, Palo Alto, CA 94303-4230, US
|
|
2002
|
|
Anacor Develops Novel Small-Molecule Therapeutics Derived From Its Boron Chemistry Platform.
|
Anacor Pharmaceuticals Alternatives
Frequently Asked Questions about Anacor Pharmaceuticals
Kevin Munoz is the CEO of Anacor Pharmaceuticals. To contact Kevin Munoz email at [email protected].
The decision makers in Anacor Pharmaceuticals are Becky Cleavenger, Carmen R Rodriguez, Emily Ip, etc. Click to Find Anacor Pharmaceuticals decision makers emails.
Anacor Pharmaceuticals Staff Directory
Search Anacor Pharmaceuticals Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
